Acura Pharmaceuticals to Develop Improved NEXAFED

Acura Pharmaceuticals ACUR today announced a second generation prototype formulation of its methamphetamine-resistant IMPEDE technology with pseudoephedrine hydrochloride yielded no measurable amount of crystal meth (the street name for the illicit drug methamphetamine hydrochloride) when processed in the direct conversion or one-pot method. Acura intends to immediately commence development of an upgraded NEXAFED [pseudoephedrine hydrochloride] Tablet using IMPEDE 2.0. NEXAFED is currently distributed through national and regional drug wholesalers to chain and independent drugstores nationwide.